The Trump administration has promoted its new TrumpRx website as a way for consumers to get the lowest prices in the world for prescription medications, drawing on voluntary pricing agreements with drug manufacturers aimed at securing “Most Favored Nation” prices for American consumers.
A KFF analysis, however, finds that consumers who buy brand-name prescription drugs without an available generic or biosimilar at TrumpRx website prices are just as likely to pay higher prices as lower prices for those drugs when compared to the publicly listed prices available in similarly wealthy countries.
The analysis compares the prices of 32 brand-name drugs listed on the TrumpRx website with those in other countries. Here are three key findings:
- For 17 of the 32 drugs, the TrumpRx price is lower than the average price in comparable countries. This includes five drugs for which the TrumpRx price is lower than the prices available in any of the other countries. Eight drugs have a price that is $100 less than the average in other countries.
- For the other 15 drugs, the TrumpRx price is higher than the average price in comparable countries. This includes 13 drugs for which the TrumpRx price is higher than prices available in any of the other countries.
- There are wide variations in price differences between TrumpRx and other countries. For nine of the drugs, the prices on TrumpRx are at least double the average across other countries. This includes Enbrel, a drug used to treat rheumatoid arthritis; the TrumpRx price is $2,725 higher than the average across other countries ($3,354 versus $641).
“There are a variety of ways to evaluate differences in drug prices across countries, with different data sources and potential price adjustments,” according to the report. “This analysis compares the retail price from TrumpRx to the publicly listed price in other countries with prices converted to U.S. dollars but unadjusted for a country’s cost of living. Comparison prices in peer nations may not necessarily reflect the out-of-pocket costs paid by an individual living in and being covered by the healthcare system in these countries.”
Comparable countries in this study included Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom for the brand-name drugs listed on the TrumpRx site (as of August 25, 2026) that do not have generics or biosimilars available in the U.S. and that had publicly available prices in at least one of the other nations. It does not compare the prices available on TrumpRx now to the prices that may have been available to consumers in the U.S. prior to its launch.
It’s worth noting that for many brand-name drugs listed on TrumpRX, the website directs consumers to manufacturers’ discount coupons to get the drugs at a pharmacy without using insurance.